Cancer Therapeutics Biotherapeutic Market Research Report By Therapeutic Modality (Monoclonal Antibodies, Small Molecules, Peptides and Proteins, Gene Therapies, Viral Therapies), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma), By Treatment Line (First-Line Therapy, Second-Line Therapy, Third-Line Therapy and Beyond), By Target Mechanism (Immuno-Oncology, Anti-Angiogenic, PARP Inhibition, EGFR Inhibition, ALK Inhibition) and By Regional (North America, Europe, South America, Asia Pacific, Middle Ea

Global Cancer Therapeutics Biotherapeutic Market Overview

As per MRFR analysis, the Cancer Therapeutics Biotherapeutic Market Size was estimated at 203.42 (USD Billion) in 2022. The Cancer Therapeutics Biotherapeutic Market Industry is expected to grow from 222.91(USD Billion) in 2023 to 507.6 (USD Billion) by 2032. The Cancer Therapeutics Biotherapeutic Market CAGR (growth rate) is expected to be around 9.58% during the forecast period (2024 - 2032).

Key Cancer Therapeutics Biotherapeutic Market Trends Highlighted

The rising prevalence of cancer and increasing unmet medical needs continue to drive the demand for advanced and effective cancer therapeutics. Biotherapeutics, particularly targeted therapies and immunotherapies, play a crucial role in addressing the limitations of traditional treatments.

Key market drivers include technological advancements in drug discovery and development, growing recognition of the role of personalized medicine, and increasing government support for research and innovation. 

These advancements are leading to the development of more precise and effective therapies, offering improved outcomes for patients. Additionally, the shift towards value-based reimbursement models is incentivizing manufacturers to develop cost-effective and innovative biotherapeutics.

Emerging trends in the market include the adoption of combination therapies, biomarker-driven drug development, and the use of artificial intelligence and machine learning in drug discovery. These advancements are expected to enhance the efficacy and personalization of cancer treatment, leading to better patient outcomes and improved quality of life. Opportunities exist for manufacturers to explore new indications, develop companion diagnostics, and leverage partnerships to enhance their position in the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Cancer Therapeutics Biotherapeutic Market Drivers

• 
  

  Increasing Prevalence of Cancer Worldwide

  
  

Cancer, being one of the most common causes of death throughout the world, has been increasing its incidence. According to the World Health Organization, there were about 19.3 million new cases and 10.0 million deaths in 2020. The number is expected to increase to 28.4 million new cases and 16.3 million deaths by 2040. Consequently, such a high frequency of cancer occurrence drives the Cancer Therapeutics Biotherapeutic Market Industry. When the number of cancer patients grows, there is also an increase in demand for efficient treatment.

Cancer therapeutics biotherapeutics is a novel class of drugs with a lot of treatment potential for different types of cancers. These drugs are intended to inhibit the activity of particular molecules or pathways responsible for the development or progression of a given cancer. While compared with some target-specific small molecules, biotherapeutics may be somewhat more effective and specific. Nevertheless, the efficacy and safety of these drugs are still improved, so the cancer therapeutics biotherapeutics are likely to remain the major type of treatment.

Rising Demand for Personalized Medicine

Personalized medicine is a medical approach that deals with the tailoring of medical prevention, diagnosis, or treatment to the individual characteristics of a patient. The characteristics taken into consideration are mostly the patient’s genetic content, as well as the environmental and lifestyle factors that increase or decrease the chances of contracting a particular disease or getting good treatment. The objective of personalized medicine is to make the treatment more efficient and adaptable to the needs of a patient. Since the emergence of this new approach, it has been realized that it is more effective than the general one-size-fits-all approach.

In cancer treatment, for instance, the use of cancer therapeutics and nutritional biotherapeutics can be personalized to suit the genetic needs of a patient. The genetic testing of a patient’s cancer can reveal the mutations causing the same and thus recommend the most effective cancer therapeutics biotherapeutic. Through this personalized biotherapy, once the therapy is effective and efficient and the patients’ cancer cases start decreasing, they can then start reducing their diet to a maintenance level where their diet can be compared against a person/individual having the same functional state of the immune system.

Personalized biotherapy provides the best treatment as the therapy is handpicked through the doctor’s prescription of the best diet for cancer patients during their treatment.

Technological Advancements in Cancer Research

Advancements in technology are key drivers of the development of new biotherapeutics for cancer. The technological advancements that are influencing the development of cancer therapeutics biotherapeutics include the introduction of new gene editing technologies like CRISPR-Cas9 and the introduction of new methods of delivering drugs to tumors. These advancements have made it possible to develop new biotherapeutics for cancer that are more effective and less toxic than traditional treatments.

In the future, as these technologies continue to advance, they will continue to spur growth.

Cancer Therapeutics Biotherapeutic Market Segment Insights

Cancer Therapeutics Biotherapeutic Therapeutic Modality Insights

The Cancer Therapeutics Biotherapeutic Market is segmented by Therapeutic Modality into Monoclonal Antibodies, Small Molecules, Peptides and Proteins, Gene Therapies, and Viral Therapies. The Monoclonal Antibodies segment is expected to hold the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. The growth of this segment can be attributed to the increasing adoption of monoclonal antibodies for the treatment of various types of cancer, such as breast cancer, lung cancer, and colorectal cancer.

The Small Molecules segment is expected to witness significant growth during the forecast period, owing to the development of novel small molecule drugs with improved efficacy and safety profiles. The Peptides and Proteins segment is also expected to grow steadily, driven by the increasing use of peptides and proteins in combination therapies. The Gene Therapies and Viral Therapies segments are expected to experience moderate growth over the forecast period as these therapies continue to gain acceptance in the treatment of cancer. The growth of the market can be attributed to the increasing prevalence of cancer, the rising adoption of biotherapeutics, and the development of novel cancer treatments.

The market is also driven by the increasing demand for personalized and targeted therapies and the growing focus on early detection and diagnosis of cancer. Key Market Insights The Monoclonal Antibodies segment is expected to hold the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. The small Molecules segment is expected to witness significant growth during the forecast period, owing to the development of novel small molecule drugs with improved efficacy and safety profiles.

The Peptides and Proteins segment is also expected to grow steadily, driven by the increasing use of peptides and proteins in combination therapies. The Gene Therapies and Viral Therapies segments are expected to experience moderate growth over the forecast period as these therapies continue to gain acceptance in the treatment of cancer. The North American region is expected to hold the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. 6. The Asia-Pacific region is expected to witness significant growth during the forecast period, owing to the increasing prevalence of cancer and the rising adoption of biotherapeutics in the region.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Cancer Therapeutics Biotherapeutic Cancer Type Insights

The Cancer Therapeutics Biotherapeutic Market is segmented by Cancer Type into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Melanoma. Breast Cancer held the largest market share in 2023, accounting for over 25% of the global market revenue. Lung Cancer is expected to be the fastest-growing segment during the forecast period, with a CAGR of over 10%. The increasing prevalence of these cancers, coupled with the development of innovative targeted therapies, is driving the growth of the Cancer Therapeutics Biotherapeutic Market.

For instance, in 2023, the global incidence of Breast Cancer was estimated to be over 2.3 million cases, while Lung Cancer accounted for over 2.2 million cases. The rising adoption of personalized medicine and immunotherapy approaches is further contributing to the market growth.

Cancer Therapeutics Biotherapeutic Treatment Line Insights

The Treatment Line segment plays a pivotal role in the Cancer Therapeutics Biotherapeutic Market, with each line representing a distinct treatment approach for cancer patients. First-Line Therapy, the initial course of treatment, accounted for the largest revenue share in 2023, estimated at approximately 40% of the Cancer Therapeutics Biotherapeutic Market. Second-Line Therapy, employed when First-Line Therapy proves ineffective or the cancer recurs, captured a significant market share of around 30%. Third-Line Therapy and Beyond, encompassing subsequent treatment options, comprised the remaining market share.

The market growth for each Treatment Line segment varies based on factors such as cancer prevalence, treatment efficacy, and reimbursement policies. First-Line Therapy remains the most lucrative segment due to the high number of newly diagnosed cancer patients requiring immediate treatment. Second-Line Therapy also holds a substantial market share, driven by the need for alternative treatment options as cancer progresses or becomes resistant to initial therapies. Third-Line Therapy and Beyond, while representing a smaller market share, is expected to witness steady growth as advancements in cancer research lead to the development of newer and more effective treatments.

Cancer Therapeutics Biotherapeutic Target Mechanism Insights

The Cancer Therapeutics Biotherapeutic Market is segmented based on the Target Mechanism into Immuno-Oncology, Anti-Angiogenic, PARP Inhibition, EGFR Inhibition, and ALK Inhibition. The Immuno-Oncology segment is expected to hold the largest market share of around 42.5% in 2023 and is projected to grow at a CAGR of 10.2% during the forecast period. The growth of the segment is attributed to the increasing adoption of immunotherapies for the treatment of various types of cancer, such as melanoma, lung cancer, and bladder cancer. The Anti-Angiogenic segment is expected to hold the second-largest market share of around 27.8% in 2023 and is projected to grow at a CAGR of 9.8% during the forecast period.

The growth of the segment is attributed to the increasing use of anti-angiogenic drugs for the treatment of cancer, such as bevacizumab (Avastin) and sunitinib (Sutent). The PARP Inhibition segment is expected to hold the third-largest market share of around 15.6% in 2023 and is projected to grow at a CAGR of 11.2% during the forecast period. The growth of the segment is attributed to the increasing use of PARP inhibitors for the treatment of cancer, such as olaparib (Lynparza) and rucaparib (Rubraca). The EGFR Inhibition segment is expected to hold the fourth-largest market share of around 9.3% in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period.

The growth of the segment is attributed to the increasing use of EGFR inhibitors for the treatment of cancer, such as erlotinib (Tarceva) and gefitinib (Iressa). The ALK Inhibition segment is expected to hold the smallest market share of around 4.8% in 2023 and is projected to grow at a CAGR of 11.7% during the forecast period. The growth of the segment is attributed to the increasing use of ALK inhibitors for the treatment of cancer, such as crizotinib (Xalkori) and ceritinib (Zykadia).

Cancer Therapeutics Biotherapeutic Regional Insights

North America is expected to hold the largest share of the Cancer Therapeutics Biotherapeutic Market in 2023, valued at USD 89.49 billion. The region's dominance can be attributed to factors such as the presence of a large patient population, well-established healthcare infrastructure, and favorable reimbursement policies. Europe is projected to be the second-largest market, with a valuation of USD 56.34 billion in 2023, driven by increasing awareness about cancer and advancements in research and development. APAC is anticipated to witness significant growth over the forecast period, owing to rising disposable income, improving healthcare systems, and increasing prevalence of cancer.

South America and MEA are expected to contribute a smaller share to the global market, but they are projected to exhibit steady growth due to government initiatives aimed at improving healthcare access and infrastructure.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Cancer Therapeutics Biotherapeutic Market Key Players And Competitive Insights

The companies’ activity in the Cancer Therapeutics Biotherapeutic Market is permeated by the pursuit of competitive advantage through a dynamic product strategy based on developmental pursuit and targeting global expansion of distribution capacity to serve the growth of emerging markets. It can be said that F. Hoffmann-La Roche Ltd. holds a particular position among these players since its product portfolio includes different targeted, immunotherapeutic, and cellular therapeutic systems of cancer regression. Owing to its firm footing in such a prevalent modern medical trend as precision medicine and personalized treatments, it seems capable of generating innovative solutions in the sphere. 

This company is also active in mergers and acquisitions and cooperation with SMEs aimed at filling in the gaps through which its competitors might enter new market niches with their products.

The activity of such a significant player in the sphere of oncology as Merck Co., Inc. is another example of a company’s dynamic product strategy. Its oncological range comprises of HER/2 tumor drug Herceptin, the most popular product in the industry, new generation xeloda cytostatics, Perjeta, Avastin, and erkuda that registered the highest sales rate among cancer biotherapeutics targeting different types of tumors. The company’s work on the augmentation of the pipeline and formation of an innovative approach to treatment is reflected in its ambitious clinical programs for the study of a wide range of indicators for selecting the most effective targeted drugs simulating the course of cancer and the appearance of resistance factors. 

The M, in synergy with SMEs, the Two Companies working on the identification and set through different liquid media, and the Antibiotics and the Antivirals platforms named the Specialists, teach that the company intends to preserve its leadership in the market.

Key Companies in the Cancer Therapeutics Biotherapeutic Market Include:

• Roche


• Merck


• Pfizer


• BristolMyers Squibb


• GlaxoSmithKline


• Gilead Sciences


• Celgene Corporation


• Bayer


• Novartis


• AbbVie


• AstraZeneca


• Amgen


• Sanofi


• Johnson Johnson


• Eli Lilly and Company

Cancer Therapeutics Biotherapeutic Market Industry Developments

The Cancer Therapeutics Biotherapeutic Market is projected to reach USD 507.6 billion by 2032, exhibiting a CAGR of 9.58% during the forecast period (2024-2032). The market growth is primarily driven by the rising prevalence of cancer, increasing adoption of personalized medicine, and technological advancements in biotherapeutics.

Recent news developments in the market include:

 In 2023, Merck Co. received FDA approval for its anti-PD-1 therapy, Keytruda, for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

 In 2022, Bristol Myers Squibb received FDA approval for its CAR T-cell therapy, Breyanzi, for the treatment of relapsed or refractory large B-cell lymphoma.

These developments indicate the growing importance of immunotherapy and targeted therapies in the cancer therapeutics landscape.

Cancer Therapeutics Biotherapeutic Market Segmentation

Cancer Therapeutics Biotherapeutic Therapeutic Modality Outlook

• Monoclonal Antibodies


• Small Molecules


• Peptides and Proteins


• Gene Therapies


• Viral Therapies

Cancer Therapeutics Biotherapeutic Cancer Type Outlook

• Breast Cancer


• Lung Cancer


• Colorectal Cancer


• Prostate Cancer


• Melanoma

Cancer Therapeutics Biotherapeutic Treatment Line Outlook

• First-Line Therapy


• Second-Line Therapy


• Third-Line Therapy and Beyond

Cancer Therapeutics Biotherapeutic Target Mechanism Outlook

• Immuno-Oncology


• Anti-Angiogenic


• PARP Inhibition


• EGFR Inhibition


• ALK Inhibition

Cancer Therapeutics Biotherapeutic Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa